3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
2
Completed
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Dalteparin
7
apixaban
5
edoxaban
4
Rivaroxaban
3
Enoxaparin
3
Tinzaparin
2
Heparin
2
Fondaparinux
2
Dabigatran
2
calcium heparin
1
bemiparin
1
Warfarin
1
Ultrasonography, Doppler, Duplex
1
Rosuvastatin Calcium
1
Nadroparin
1
Heparin, Low-Molecular-Weight
1
Data Collection
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Venous Thrombosis
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled
NCT00967148
2014-10-22
PERI-OP
Ottawa Hospital Research Institute
Phase NA
Completed
18 enrolled